Orçun Can

Orçun Can

Auto-generated profile, based on publicly available information

Orçun Can

Acibadem Mehmet Ali Aydinlar University, Faculty of Medicine, Department of Medical Oncology, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in European Journal of Breast Health
Verified
Journal Article
Closed access
MAMuhammed Mustafa Atcı
Muhammed Mustafa Atcı
ÇGÇağlayan Geredeli
Çağlayan Geredeli
SESeval Ay Ersoy
Seval Ay Ersoy
ASAbdullah Sakin
Abdullah Sakin
BEBiray Ertürk
Biray Ertürk
MGMahmut Gumus
Mahmut Gumus
This study aimed to determine the differences in clinicopathological features of Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer susceptibility genes (BRCA1/2) . This study enrolled patients with invasive breast cancer who have been evaluated for BRCA1/2 mutations due to the presence of high-risk factors admitted to two tertiary referral centers in Turkey. Clinical and histopathological features were analyzed in BRCA1 mutation carriers, BRCA2 mutation carriers, and non-carriers. A total of 302 patients with a mean age of 44.2±9.9 (22–82) years were included. BRCA1/2 mutation was found in 75 (24%) patients, of whom 41 (13.6%) were BRCA1 mutation carriers and 37 (12.3%) were BRCA2 mutation carriers. Moreover, 104 (34.4%) and 4 (1.3%) patients had family history of breast and ovarian carcinoma, respectively. The rates of triple negativity (56.1%), histologic grade 3 (65.9%), and lymphovascular invasion (78%) were significantly higher in BRCA1 mutation carriers than in non-carriers and BRCA2 mutation carriers. Furthermore, 87% of triple-negative BRCA1 mutation carriers had histologic grade 3 tumors compared with 38.9% in non-triple-negative BRCA1 mutation carriers, and the difference was significant. Findings of this study showed that BRCA1-related breast cancers represent a distinct group with unique pathological features, which are usually associated with a poor prognosis.

1 September 2019 in Journal of Surgical Research
Verified
Journal Article
Closed access
ASAbdullah Sakin
Abdullah Sakin
OCOrcun Can
Orcun Can
SASerdar Arici
Serdar Arici
NYNurgul Yasar
Nurgul Yasar
CGCaglayan Geredeli
Caglayan Geredeli
SCSener Cihan
Sener Cihan

1 October 2024 in Indian Journal of Cancer
Verified
Journal Article
Open access
MAMuhammed M. Atci
Muhammed M. Atci
SSSaban Secmeler
Saban Secmeler
ASAbdullah Sakin
Abdullah Sakin
SASerdar Arici
Serdar Arici
OCOrcun Can
Orcun Can
SCSener Cihan
Sener Cihan
Background: We aimed to evaluate the data of perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy regimen in locally advanced gastric cancer (LAGC) patients with real-life experience. Methods: In this retrospective study, LAGC patients who received perioperative FLOT chemotherapy regimen between 2017 and 2020 were included. The patients were grouped according to tumor regression grade (TRG): histopathological responders (complete/moderate response) and histopathological non-responders (minimal/poor response). The factors affecting TRG were evaluated and its relationship to clinical outcome was analyzed by disease-free survival (DFS) and overall survival (OS). Results: A total of 141 LAGC patients were included. Median age of patients was 62 (range: 35–75) years of whom 69.5% were men. According to TRG, 41 (29.1%) patients were histopathological responders (College of American Pathologists (CAP)-TRG 0/1). Grade, perineural and lymphovascular invasion, clinical stage, tumor markers (Carcinoembryonic antigen (CEA) and Carbohydrate antigen (CA)19-9), radiological response, and ypTNM stage were statistically significant in univariate analysis and lymphovascular invasion was detected as an independent factor in multivariate analysis for TRG. Grade 3-4 toxicities were observed in only 28 (19.9%) patients. Two years DFS and OS rates were higher in the histopathological responder group (100% and 100%) compared to the histopathological non-responder group (59% and 52.9%) (P = 0.01 and P = 0.02, respectively). Conclusion: In our study, it was found that the FLOT regimen had a favorable TRG and a safe toxicity profile in gastric cancer patients. In addition, while lymphovascular invasion could predict TRG, the survival and disease recurrence were positively affected by the favorable TRG response.

3 May 2020 in The European Research Journal
Verified
Journal Article
Open access
PDF file
SASerdar Arıcı
Serdar Arıcı
ÇGÇağlayan Geredeli
Çağlayan Geredeli
ŞSŞaban Seçmeler
Şaban Seçmeler
ASAbdullah Sakin
Abdullah Sakin
OCOrçun Can
Orçun Can
ŞCŞener Cihan
Şener Cihan
Objectives: To determine fulvestrant efficacy and tolerability in Turkish patients with hormone receptor-positive metastatic breast cancer.Methods: Patients who developed metastasis while taking tamoxifen or aromatase inhibitors in the adjuvant period or metastatic disease at the diagnosis. Fulvestrant 500 mg was administered intramuscularly every 28 days. Progression-free survival (PFS) and overall survival (OS) durations were calculated.Results: In this particular research, totally 137 patients were participated. Median PFS was 9 months (95% CI, 5.7-10.3). The 12-month PFS rate was calculated as 42%, and the 36-month PFS rate was 17%. The median PFS was not reached in the first line use of fulvestrant in the metastatic period but 9 months and 7 months in the second and subsequent lines respectively. Results indicated that this difference was statistically significant (p = 0.002). It was shown that patients with liver and brain metastasis had lower PFS compared patients with no liver and no brain metastasis. The estimated median OS was 38 months after fulvestrant started. The 12-month OS rate was calculated as 82.4%, and the 36-month OS rate was 50%. Conclusions: Fulvestrant contributes both PFS and OS in patients with hormone receptor-positive metastatic breast cancer and this effect is more clear in using fulvestrant as first-line treatment.

7 August 2025
Verified
Book Chapter
Closed access
OCOrçun Can
Orçun Can
Timoma ve timik karsinom, timüs epitel tümörleri arasında nadir görülen ancak uzun vadede ciddi takip gerektiren malignitelerdir. Timoma daha az agresif seyrederken, timik karsinom daha kötü prognoza sahip ve nüks riski yüksek bir tümördür. Tedavi sonrası takip, hastalığın nüksünü erken tespit etmek ve otoimmün komplikasyonları yönetmek açısından kritik öneme sahiptir. Standart takip protokolü, intravenöz kontrastlı bilgisayarlı tomografi (BT) ile düzenli görüntüleme yapılmasını içerir. Evre I timoma ve timik karsinom vakalarında ilk iki yıl boyunca 6 ayda bir, sonrasında timoma için 10 yıl, timik karsinom için 5 yıl yıllık BT ile takip önerilir. Daha ileri evre vakalarda bu sıklık, ilk iki yıl boyunca 3-6 ayda bir kontrastlı BT olacak şekilde artırılmalıdır. Nüksler genellikle cerrahiden sonraki ilk 3 ila 7 yıl içinde görülür ve tam cerrahi çıkarım sağkalımı olumlu etkiler. Rezeke edilemeyen nükslerde kemoterapi ve radyoterapi seçenekleri değerlendirilmelidir. Takip sürecinde sekonder malignite gelişme riski de artmıştır ve timoma hastalarında lenfoma, gastrointestinal kanserler ve yumuşak doku sarkomlarının daha sık görüldüğü bildirilmiştir. Takip protokolü yalnızca nükslerin değil, bu kanserlerin erken teşhisini de içermelidir. Ayrıca, otoimmün komplikasyonlar açısından özellikle miyastenia gravis takibi önemlidir ve anti-asetilkolin reseptör antikorlarının düzenli izlenmesi önerilmektedir. Ameliyat sonrası miyastenia gravis gelişimi, asemptomatik hastalarda bile ortaya çıkabilir ve bu durum takip protokollerine dahil edilmelidir. Takip sürecinde geç toksisite ve tedaviye bağlı komplikasyonlar da izlenmeli, hastaların uzun vadede düzenli aralıklarla değerlendirilmesi sağlanmalıdır. Nükslerin geç dönemlerde de görülebilmesi nedeniyle takip süreci en az 10-15 yıl sürdürülmeli ve bu süreçte moleküler hedefe yönelik tedavilerle kişiselleştirilmiş izleme protokolleri geliştirilmelidir. Thymoma and thymic carcinoma are rare malignancies among thymus epithelial tumors but require serious long-term follow-up. While thymoma is less aggressive, thymic carcinoma has a worse prognosis and a high risk of recurrence. Post-treatment follow-up is critical for early detection of disease recurrence and management of autoimmune complications. The standard follow-up protocol includes regular imaging with intravenous contrast-enhanced computed tomography (CT). In stage I thymoma and thymic carcinoma cases, follow-up with CT is recommended every 6 months for the first two years, then every 10 years for thymoma and every 5 years for thymic carcinoma. In more advanced cases, this frequency should be increased to every 3-6 months for the first two years with contrast-enhanced CT. Recurrences are usually seen within the first 3 to 7 years after surgery, and complete surgical removal positively affects survival. Chemotherapy and radiotherapy options should be considered in unresectable recurrences. The risk of developing secondary malignancies has also increased during the follow-up period, and lymphoma, gastrointestinal cancers, and soft tissue sarcomas have been reported to be more common in thymoma patients. The follow-up protocol should include not only recurrences but also early diagnosis of these cancers. In addition, myasthenia gravis follow-up is especially important in terms of autoimmune complications, and regular monitoring of anti-acetylcholine receptor antibodies is recommended. Postoperative myasthenia gravis development can occur even in asymptomatic patients, and this should be included in follow-up protocols. Late toxicity and treatment-related complications should also be monitored during the follow-up period, and patients should be evaluated at regular intervals in the long term. Since recurrences can also be seen in the late stages, the follow-up period should be continued for at least 10-15 years, and personalized monitoring protocols should be developed with molecular targeting treatments during this period.

31 August 2026 in Medical Journal of Western Black Sea
Verified
Journal Article
Closed access
OCOrçun Can
Orçun Can
ODOsman Gökhan Demir
Osman Gökhan Demir
Aim: Trastuzumab deruxtecan (T-DXd) has shown substantial activity in trials of HER2-positive metastatic breast cancer (mBC), but real-world data in heavily pretreated patients, in those with CNS metastases, and in patients started at reduced doses remain limited. To evaluate real-world efficacy and safety of T-DXd in HER2-positive mBC, focusing on late-line use, CNS disease, and reduced-dose initiation.Material and Methods: This retrospective single-center cohort included 42 consecutive HER2-positive mBC patients treated with T-DXd between September 2023 and December 2025. HER2 positivity required IHC 3+ or IHC 2+/ISH-positive. Baseline CNS metastases were present in 16 patients (38.1%); 81.0% received T-DXd as fourth-line therapy or later. T-DXd was initiated at 3.6 mg/kg in 34 patients (81.0%) and at 5.4 mg/kg in 8 (19.0%). Primary endpoints were real-world progression-free (rwPFS) and overall survival (rwOS); secondary endpoints were disease control rate (DCR) and safety. Results: At a median follow-up of 16.2 months, median rwPFS was 14.4 months (95% CI: 10.8–18.0) and median rwOS was not reached. ORR was 67.5% and DCR 90.0% (n=40 evaluable). In the CNS subgroup, ORR was 62.5% and rwPFS 13.2 months; in the 3.6 mg/kg subgroup, ORR was 64.7% and rwPFS 14.1 months. Any-grade adverse events occurred in 59.5%, grade ≥3 in 11.9%; ILD/pneumonitis in 4.8% (all grade 1–2).Conclusion: T-DXd showed meaningful, sustained real-world activity in heavily pretreated HER2-positive mBC, including CNS disease and reduced-dose initiation, warranting prospective confirmation.